Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant.

MLA

Litton, Jennifer K., et al. “Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant.” Journal of Clinical Oncology, vol. 38, no. 5, Feb. 2020, pp. 388–94. EBSCOhost, https://doi.org/10.1200/JCO.19.01304.

APA

Litton, J. K., Scoggins, M. E., Hess, K. R., Adrada, B. E., Murthy, R. K., Damodaran, S., DeSnyder, S. M., Brewster, A. M., Barcenas, C. H., Valero, V., Whitman, G. J., Schwartz-Gomez, J., Mittendorf, E. A., Thompson, A. M., Helgason, T., Ibrahim, N., Piwnica-Worms, H., Moulder, S. L., & Arun, B. K. (2020). Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant. Journal of Clinical Oncology, 38(5), 388–394. https://doi.org/10.1200/JCO.19.01304

Chicago

Litton, Jennifer K., Marion E. Scoggins, Kenneth R. Hess, Beatriz E. Adrada, Rashmi K. Murthy, Senthil Damodaran, Sarah M. DeSnyder, et al. 2020. “Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant.” Journal of Clinical Oncology 38 (5): 388–94. doi:10.1200/JCO.19.01304.